Fetal weight is an important index to judge fetal development and ensure the safety of pregnant women. However, fetal weight cannot be directly measured. This study proposed a prediction model of fetal weight based on genetic algorithm to optimize back propagation (GA-BP) neural network. Using random number table method, 80 cases of pregnant women in our hospital from September 2018 to March 2019 were divided into control group and observation group, 40 cases in each group. The doctors in the control group predicted the fetal weight subjectively according to routine ultrasound and physical examination. In the observation group, the continuous weight change model of pregnant women was established by using the regression model and the historical physical examination data obtained by feature normalization pretreatment, and then the genetic algorithm (GA) was used to optimize the initial weights and thresholds of back propagation (BP) neural network to establish the fetal weight prediction model. The coincidence rate of fetal weight was compared between the two groups after birth. Results: The prediction error of GA-BPNN was controlled within 6%. And the accuracy of GA-BPNN was 76.3%, which were 14.5% higher than that of traditional methods. According to the error curve, GA-BP is more effective in predicting the actual fetal weight. Conclusion: The GA-BPNN model can accurately and quickly predict fetal weight.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3934/mbe.2021222 | DOI Listing |
Arch Gynecol Obstet
January 2025
Faculty of Health Sciences, Kocaeli Health and Technology University, Kocaeli, Türkiye.
Introduction: According to the World Health Organization, adolescent pregnancy is defined as pregnancies of women aged 19 and below. The study aims to analyze the rates of adolescent pregnancies and maternal and fetal outcomes among births within the hospital and compare them with adult pregnancies.
Methods: The study is conducted retrospectively in one of Turkey's socio-economically underdeveloped provinces.
BMJ Case Rep
January 2025
Neonatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Sulfasalazine is a non-specific immunomodulator with haemolytic anaemia as a known side effect that crosses the placenta. We present a preterm neonate with cardiac arrhythmia secondary to hyperkalaemia in the setting of maternal sulfasalazine therapy. A preterm infant was born to a mother taking hydroxychloroquine, sulfasalazine, aspirin and enoxaparin throughout pregnancy.
View Article and Find Full Text PDFBackground: Obesity during pregnancy is related to fetal overgrowth. Effective interventions that can mitigate this risk are needed.
Objectives: This study aimed to investigate the effect of a lifestyle intervention for pregnant women with obesity on fetal growth trajectories.
Rev Gastroenterol Peru
January 2025
Department of Pathology, Santa Casa Hospital, Porto Alegre, Brazil.
Pancreatic ductal adenocarcinoma during pregnancy is extremely rare. Overall, including our case, only 19 cases confirmed antepartum have been reported to date. We report the case of a 37 year-old woman at 24 weeks of pregnancy in whom a pancreatic adenocarcinoma was identified during investigation of a suspected acute pancreatitis.
View Article and Find Full Text PDFUltrasound Obstet Gynecol
January 2025
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Objectives: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre-eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor.
Methods: This was a prospective case-control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!